GPT and metabolic dysfunction-associated steatohepatitis: Studies on rifaximin, active on Gram-negative bacteria, show conflicting results in NASH patients ranging from a significant reduction of ALT, endotoxin and IL-10 levels [108] to the inefficacy on fat liver content and ALT levels [109].